New York, May 18, 2026, 06:05 EDT
- CMPS traded at about $12.4 before the bell, up roughly 20% from Friday’s finish.
- Compass said it has a quicker FDA route for COMP360. Now, attention turns to a Tuesday RBC investor event.
- The main risk is whether moving fast leads to approval, reimbursement, and a launch that works.
Compass Pathways plc jumped in U.S. premarket action Monday as the stock built on last week’s gains. Investors are reacting to signs of a quicker path for COMP360, the company’s psilocybin drug candidate for depression. The Nasdaq shares traded at $12.39 at 6:03 a.m. EDT, up 19.5% from Friday’s close at $10.37. Regular trading on Nasdaq begins at 9:30 a.m. Eastern.
Compass has shifted its focus from trial data to seeking full approval. Last week, the company said the U.S. Food and Drug Administration allowed it to submit its New Drug Application in parts. That rolling submission means Compass can send pieces of the approval file as they’re ready, instead of waiting until it’s finished.
Management is set to take investor questions at 10:00 a.m. ET Tuesday during a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York. Compass said investors can access a replay for 30 days.
COMP360 is Compass’ lab-made psilocybin for treatment-resistant depression, where patients see poor results from regular drugs. The company says this synthetic version of the magic mushroom compound has FDA Breakthrough Therapy status and is included in the U.K. Innovative Licensing and Access Pathway.
Kabir Nath, chief executive, said “regulatory acceleration” is happening, and called COMP360 a different option for patients with treatment-resistant depression. Compass aims to finish a “robust clinical package” by the fourth quarter, he said. SEC
COMPASS said COMP360 got a Commissioner’s National Priority Voucher, which could shorten the review period to one or two months, according to the company. It expects 26-week data from its COMP006 Phase 3 trial early in the third quarter of 2026 and kept guidance for final NDA submission in the fourth quarter.
Cash is a factor for bulls. Compass finished March holding $466.0 million in cash and equivalents, up from $149.6 million at December’s close. The company said this should fund operations into 2028.
Compass’s first-quarter numbers need a closer look. The company posted net income of $91.2 million, but that figure got a $130.9 million lift from a non-cash gain on warrant liabilities. Its operating loss for the quarter was $42.9 million. R&D spending dropped to $26.5 million from $30.9 million one year ago.
Compass Pathways saw new analyst targets after the latest update. Maxim’s Jason McCarthy lifted his price target to $20 from $12, sticking with a Buy. He said the priority voucher should make commercial timelines faster. StockAnalysis also flagged recent target hikes from Morgan Stanley’s Judah Frommer and RBC Capital’s Leonid Timashev.
Competition in the space is getting tougher. Johnson & Johnson’s Spravato remains the approved supervised-treatment standard for treatment-resistant depression. Development-stage names like AtaiBeckley and GH Research are pushing forward on psychedelic or related depression treatments. Compass points to more than 7,300 centers already set up for multi-hour treatments, saying COMP360 could slot into current healthcare sites.
But Compass spelled out the risks. The company said full Phase 3 safety data could come in differently than results so far. Rolling review or the CNPV program might not actually get the FDA to review or approve faster. Commercialization, insurance coverage, and reimbursement could still miss targets.
Right now, the stock is moving mostly on timing instead of just the science. The big question is whether management can persuade investors this week that speeding up the filing also makes launching outside the trial possible.
